Roberto Barriales-Villa
@rbarvil
Born in Mieres del Camino (Asturias); Cardiologist; Inherited Cardiovascular Diseases - Genetics at Complexo Hospitalario Universitario A Coruña #SomosCHUAC
Abordaje y consumo de recursos sanitarios en la miocardiopatía hipertrófica obstructiva en España: un estudio de la vida real #REC #Aheadofprint @rbarvil @LuisEscobarL revespcardiol.org/es-abordaje-y-…
Enlace a FabryLink 👉linkedin.com/groups/1312798… #Fabry #FabryLink #RedFabry
🔔 We’ve extended the abstract submission deadline to August 4! There’s still time to share your work & insights with top international experts. 📢 Easy submission guidelines here: 🌐 hypertrophiccardiomyopathyacoruna.com/abstracts/
💜The time has finally come to share our book ‘My Heart Speaks’ in English. We hope you like it! You can find it at the link: angelsfortuneditions.com/libro/my-heart… 📖In this book, family members and patients wit HCM @BMSIberia @aemchipertrofica #HCM #MCH #AEMCH #MiCorazonHabla #MyHeartSpeaks
1 year data on aficamten in the FOREST HCM trial are now published in JACC Journals pubmed.ncbi.nlm.nih.gov/40540987/ #CardioTwitter
#ESCCongress is coming 'home' @escardio and @ComunidadMadrid 🇪🇦 will host the world's leading CV congress - register 🔜 @Sarah_Moharem @VDelgadoGarcia @dr_pavia @rbarvil @Borjaibanez1 @rafavidalperez @arbelo_e
Ready to take the next step in your career? Let #ESCCongress with #WCCardio lead the path to opportunity. Explore tracks tailored to every stage of your journey, including the Young Track for early-career professionals. Register now to save! bit.ly/3FXBk9k 📍Madrid,…
Estoy tremendamente ilusionado de anunciar que A Coruña acogerá el 59 Congreso de la Separ @SeparRespira ! TRADICIÓN QUE INSPIRA. INNOVACIÓN QUE TRANSFORMA
Si buscas apoyo e información sobre la enfermedad de Fabry🧬, únete a FabryLink, nuestro grupo privado en LinkedIn, para conectar con otros expertos Enlace🔗FabryLink #FabryLink #RedFabry #Fabry Dirigido exclusivamente a profesionales sanitarios. Colaboración con Sanof
Consulta de enfermedades Cardio- Neurológicas en el CHU de A Coruña. El Dr JM Larrañaga repasa el seguimiento de pacientes con estas entidades en el CFC en Cardiología de nuestro centro @jmvazrod @SOGACAR_ @SanidadeACoruna @eduardo_barge @rafavidalperez
🚨 CALL FOR ABSTRACTS! Submit your work to the V International Workshop on Cardiomyopathies – HCM 2025 🗓️ Sept 18–19 | 📍A Coruña, Spain 🧬 Case reports, cohorts, clinical trials (original + encore accepted!) 📅 Deadline: July 4 🔗 hypertrophiccardiomyopathyacoruna.com/topics 🎖️ Top 3 abstracts
Clinical management and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy in Spain: a real-world study #REC #Aheadofprint @rbarvil @LuisEscobarL revespcardiol.org/en-clinical-ma…
Obstructive hypertrophic cardiomyopathy management and its clinical and economic burden in Spain. Read this article published in @RevEspCardiol by @rbarvil @seccCFyGenetCV revespcardiol.org/en-clinical-ma…
🧳Seguimos ruta, 27 de Mayo visibilizando #aemch en #HospitalAlvaroCunqueiro con Eduardo Villacorta, Raquel Bilbao, Rafael José Cobas, equipo y pacientes, la importancia de crear conexiones #MiCorazonHabla Visitamos el 4 junio el #hospitalAbenteyLago #BMSIberia #aemchipertrofica
Lots of cardiomyopathy news these few weeks. Every patient loss is a devastating event. Always best to await the investigation, review and full details of such an event. Danon disease is a devastating and fatal disease, and as such, cannot view these events in isolation. Always…
An interesting study on clustering patients with oHCM in @JACCJournals sciencedirect.com/science/articl… Here is the editorial simplifying these complexities sciencedirect.com/science/articl… #cardiotwitter
Miocardiopatías: cuéntame las novedades en 20 min. Dra. Beatriz Díaz Molina. H.U. Central de Asturias, Oviedo @Beadimo #GalaicoAstur2025 @secardiologia @SOGACAR_ @SAsCardiologia
“If you search for it, you’ll find it”: lessons from the Spanish cohort of the p.Val142Ile amyloidosis variant #REC #Aheadofprint @rbarvil @emaralv1 @xenux88 revespcardiol.org/en-if-you-sear…
3 out of 7 newly diagnosed ATTR-CM patients that I saw in 1 day didnt have ATTR-CM (2 on therapy). Just really tough to interpret PYP scans with blood pooling, and due to cavity size and shape they simply appeared as myocardial uptake to those reading them. That is why we are…
An important analysis. Aficamten effect is consistent regardless of symptom severity in obstructive HCM. In a remodeled ventricle with significant limitations in exercise metrics and elevated NTproBNP, symptoms on their own are not really a good metric to decide on starting…
Promising early data for the novel myosin modulator EDG-7500 (catchy!) from CIRRUS HCM trial, presented by Anjali Owens and discussed by Iacopo Olivotto. Doesn’t affect LVEF so won’t need serial echo. #HeartFailure2025